Bounce Mobile Systems Inc (BNCM): BNCM is a relatively safe bet (pharmaceu...

BNCM is a relatively safe bet (pharmaceuticals in

Humbert · 2025-03-10T16:06:29.8900000Z

BNCM is a relatively safe bet (pharmaceuticals in an expanding economy) in an otherwise chaotic and stagnant world.

Play Episode

5min

Proactive - Interviews for investors

COSOL Sees U.S. market as key growth driver

COSOL Limited Managing Director Scott McGowan talked with Proactive at AIM's Small and Midcap Conference about the company’s role in driving operational efficiency across asset-intensive industries. COSOL Limited works with organisations in mining, oil and gas, utilities, and public infrastructure to enhance the performance of their physical assets. McGowan explained the company’s core service as unlocking value by helping clients reduce costs through better asset management. “We look at ways that we can save them real dollars to be able to manage that asset more effectively,” he said. The company’s client list includes major names such as Glencore, Rio Tinto, BHP, and several government departments. COSOL provides the systems and processes behind the scenes to manage these organisations’ equipment and facilities, potentially impacting hundreds of millions in operational costs. Even a 2–3% improvement, McGowan said, “makes a significant difference to their bottom line.” COSOL has grown revenue from AUD 30 million to over AUD 110 million since listing. It is now targeting organic growth in the mid-teens and exploring earnings-accretive acquisitions. McGowan also highlighted COSOL’s presence in the U.S., describing it as the company’s largest potential market, where current operations may be expanded through acquisition. #COSOL #ASXStocks #ScottMcGowan #AssetManagement #MiningTech #Utilities #PublicInfrastructure #OperationalEfficiency #DataSolutions #IndustrialSoftware #GrowthStocks #USExpansion #InvestingInTech -

Proactive - Interviews for investors

Wrkr CEO on super compliance growth strategy

Wrkr Limited CEO Trent Lund talked with Proactive at the AIM's Small and Midcap Conference about the company’s strategy to simplify compliance through a deeply integrated digital platform. The ASX-listed company, trading under the ticker WRK, connects users, employers, and superannuation funds to streamline data accuracy and reduce friction in onboarding processes. “We do all the hard work and the heavy lifting so the business and the employee don’t have to,” said Lund. He explained that Wrkr verifies user credentials and automates data flows, reducing error and increasing trust. The system connects to major superannuation funds and payroll systems, holding accurate user information even during job transitions. Lund detailed Wrkr’s monetisation model, which aims to earn approximately $7 per user through microservices, including license checks and transactions. Current pilots, including one with major fund REST, are transitioning to production. Each super fund implementation takes about nine months and represents between $7 million and $14 million in annual annuity revenue once fully operational. Looking ahead, 2025 will be focused on large-scale implementation, with 2026 anticipated to generate higher consumption-based revenues. In 2027, Wrkr expects a significant uplift with the introduction of payday super legislation. #WrkrLimited #TrentLund #ASXWRK #Superannuation #ComplianceTech #FintechAustralia #PayrollIntegration #InvestorUpdate #PaydaySuper #DigitalTransformation #DataVerification #WorkforceAutomation

Proactive - Interviews for investors

Sprintex secures A$3.25m to expand global output; reduce debt

Sprintex Ltd (ASX:SIX) managing director and CEO Jay Upton talked with Proactive's Stephen Gunnion about the company’s successful A$3.25 million capital raise, drawing strong backing from both existing shareholders and new institutional investors. Upton said approximately A$1.5 million of the funds would go toward debt reduction, with the remaining A$1.75 million allocated to accelerating production and sales of Sprintex’s new range of high-speed electric compressors. These products aim to improve energy efficiency, offering “more than 50% energy savings versus the current benchmark products”. He discussed the company’s strategic manufacturing expansion, highlighting the transition of its Malaysian facility to support electric compressor production—mirroring current operations in Suzhou, China. This move is designed to double manufacturing capacity, navigate global trade sensitivities, and better serve regional preferences. Currently in the Netherlands, Upton also outlined a five-year partnership with Mest Water, a Dutch wastewater treatment firm focused on ammonia reduction in livestock manure—a project supported by the Dutch government. Sprintex will supply compressors for this initiative. Looking ahead, Sprintex is set to exhibit at the Hannover International Trade Fair in Germany, where the company expects to attract significant attention for its clean air and vacuum solutions across industries like aquaculture, semiconductors, textiles, and agriculture. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications so you never miss an update. #Sprintex #CleanTech #IndustrialCompressors #EnergyEfficiency #GreenTechnology #CapitalRaise #Manufacturing #DutchTech #HannoverFair #VacuumTechnology #AsiaManufacturing #SustainableIndustry #AmmoniaReduction #ElectricCompressors

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Followers	21
Posts	1350
Boards Moderated	1
Alias Born	05/26/2017

Volume:	-
Day Range:
Bid:	0.0074
Ask:	0.01
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BNCM Detailed Quote

Recent BNCM News

More BNCM News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BNCM News

Go Ad-Free